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Abstract
Background: AKAP12/Gravin (A kinase anchor protein 12) is one of the A-kinase scaffold proteins and a potential tumor
suppressor gene in human primary cancers. Our recent study demonstrated the highly recurrent loss of AKAP12 in colorectal
cancer and AKAP12 reexpression inhibited proliferation and anchorage-independent growth in colorectal cancer cells,
implicating AKAP12 in colorectal cancer pathogenesis.
Methods: To evaluate the effect of this gene on the progression and metastasis of colorectal cancer, we examined the
impact of overexpressing AKAP12 in the AKAP12-negative human colorectal cancer cell line LoVo, the single clone (LoVo-
AKAP12) compared to mock-transfected cells (LoVo-CON).
Results: pCMV6-AKAP12-mediated AKAP12 re-expression induced apoptosis (3% to 12.7%, p,0.01), migration (89.667.5
cells to 31.064.1 cells, p,0.01) and invasion (82.765.2 cells to 24.763.3 cells, p,0.01) of LoVo cells in vitro compared to
control cells. Nude mice injected with LoVo-AKAP12 cells had both significantly reduced tumor volume (p,0.01) and
increased apoptosis compared to mice given AKAP12-CON. The quantitative human-specific Alu PCR analysis showed
overexpression of AKAP12 suppressed the number of intravasated cells in vivo (p,0.01).
Conclusion: These results demonstrate that AKAP12 may play an important role in tumor growth suppression and the
survival of human colorectal cancer.
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Introduction
Colorectal cancer is the third most common form of cancer in
the world and the leading cause of cancer mortality[1–3]. Better
understanding of the mechanisms underlying colorectal cancer
formation and progression is greatly needed because only modest
improvements in the survival of colorectal cancer patients have
been achieved over the last decade.
A-kinase anchor protein 12 (AKAP12/Gravin) was first isolated
as a protein recognized by the serum of myasthenia gravis
patients[4]. It is one of the A-kinase anchoring proteins (AKAPs)
that belong to a family of scaffold proteins, and organizes the
protein kinase A (PKA) and C (PKC)[5]. It is also an important
regulator of the b2-adrenergic receptor complex, which controls
cell signaling, cell adhesion, mitogenesis and differentiation[6,7].
AKAP12 has been mapped to chromosome 6q24–25.2, a cancer
deletion hotspot [8]. DNA hypermethylation in the AKAP12
promoter region, and the accompanied underexpression of the
corresponding gene, has been noted in a variety of human cancers,
including gastric cancer, esophageal cancer and lung cancer, and
in myeloma cells and myeloid malignancies[6,8–11]. Downregu-
lation of AKAP12 expression suggests that the inactivation of
AKAP12 expression may be linked to oncogenesis. A recent report
using microarray data from in silico genetic searches indicated that
methylation is associated with the downregulation of AKAP12 in
colon cancer and identified AKAP12 as a potential tumor
suppressor gene candidate[12]. In our previous study, downreg-
ulation or loss of AKAP12 mRNA expression was detected in
68.9% (31/45) of colorectal carcinoma tissues and methylation of
the AKAP12 promoter region was detected in 77.8% (35/45) of
these tissues compared with 13.3% (6/45) in the adjacent
tissue[13]. Complete loss of AKAP12 and hypermethylation of
the promoter was detected in colorectal cancer cell lines, LoVo,
SW480 and COLO320. However, it remains unclear if AKAP12
plays an inhibitory role in the progression or metastasis of
colorectal cancer.
In this report, we analyzed the effect of AKAP12 on the
tumorigenesis and metastasis of LoVo cells in vitro and in vivo. Our
data demonstrate that the re-expression of AKAP12 could inhibit
the progression and metastatic potential of colorectal carcinoma.
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24015Therefore, we propose that AKAP12 functions as a tumor
suppressor of this solid cancer.
Results
AKAP12 inhibited cell growth and induced apoptosis
To examine the impact of the AKAP12 re-expression in
colorectal cancer cells, we constructed a vector constitutively
expressing AKAP12 (pCMV6-AKAP12) to restore AKAP12 expres-
sion in LoVo cells, which lack AKAP12 expression in our previous
study[13]. We stably transfected LoVo cells with the pCMV6-
AKAP12 or empty control vector, respectively. Significant
AKAP12 mRNA and protein re-expression in LoVo-AKAP12 cells
compared with LoVo-CON was observed [13]. We also analyzed
cell proliferation using a WST assay and the growth of LoVo cells
in soft agar. Strongly inhibited the growth of LoVo cells and a
significant decrease in the number of colonies was observed when
tumor cells were transfected with pCMV6-AKAP12 [13].
Given the effects of AKAP12 on cell proliferation and viability,
using PI and Annexin V staining, we next examined whether
pCMV6-AKAP12 transfection-induced apoptosis of LoVo cells.
Flow cytometry revealed that transfection of LoVo cells with
pCMV6-AKAP12 induced a marked increased in the percentage
of apoptotic (annexin V
+ PI
2) cells compared with the LoVo cells
with control vectors (12.7% versus 3.0%, respectively; p,0.01)
(Fig. 1A). We also evaluated the expression of cleaved-caspase-3
(the active form of caspase-3, Fig. 1B) in these two cells. The results
indicate that cells transfected with the Lovo-AKAP12 can
significantly increase cleaved-caspase-3 level.
Oncosuppressive effect of AKAP12 on LoVo cells
Given that migration and invasion are key components of the
metastatic cascade, we conducted in vitro migration and invasion
assays to evaluate the migration and invasion potential of LoVo-
AKAP12 and LoVo-CON cells. Overexpression of AKAP12 lead to
an average decrease in migration of an average of 65.4% compared
to the control cells (31.064.1 versus 89.667.5 cells cells per field,
respectively; p,0.01) (Fig. 2A, B). Furthermore, overexpression of
AKAP12 lead to an average of 70.1% (24.763.3 cells versus
82.765.2 cells per field, respectively; p,0.01) decrease invasiveness
compared with the control cells (Fig. 2C, D). These results suggest
that AKAP12 expression is inversely associated with the migration
and invasion ability of colorectal cell lines LoVo in vitro.
AKAP12 inhibits tumorigenesis, metastatic and induced
apoptosis in vivo
Because AKAP12 inhibits LoVo cell growth in vitro, we further
assessed its effect on tumor formation in vivo. The anti-tumor
activity of AKAP12 was evaluated in a primary xenograft model
using nude mice. LoVo-AKAP12 cells, LoVo-CON cells and non-
transfected LoVo-LIPO cells were injected into the flank of nude
mice. Four weeks later, mice were sacrificed and examined for the
presence of metastases in the lungs. Injection of LoVo-AKAP12
cells reduced tumor volume significantly compared with the
LoVo-CON and LoVo-LIPO cells four weeks-post injection
(p,0.01) (Fig. 3A, B). To assess if AKAP12 could reduce the
formation of lung metastases, we determined the presence of Alu
sequences in the lungs of nude mice injected with each type of
LoVo cells using real-time PCR. The human tumor cell metastasis
Figure 1. Effects of AKAP12 on apoptosis of LoVo cells transfected with pCMV6-AKAP12. (A) Effects of AKAP12 expression on apoptosis in
AKAP12-transfected LoVo cells. LoVo-AKAP12 cells and LoVo-CON cells were analyzed using FACS and PI/Annexin V staining. The legends show the
percentage of cells undergoing apoptosis. (B) Western blot analysis of cleaved-caspase-3 in Lovo-CON and Lovo-AKAP12 cells. AKAP12 increase
cleaved-caspase-3 in cultured Lovo cells.
doi:10.1371/journal.pone.0024015.g001
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through the transwell chambers and were photographed at 6100 magnification. (B) The in vitro migration ability of LoVo-AKAP12 cells and LoVo-
CON cells was measured by determining the number of cells that migrated through the transwell chamber. Columns, mean values; bar, SD. * p,0.01.
(C) LoVo-AKAP12 and LoVo-CON cells that migrated through the transwell chambers and photographed at 6100 magnification. (D) The in vitro
migration ability of LoVo-AKAP12 cells and LoVo-CON cells was measured by determining the number of matrigel-coated cells that penetrated
through the transwell chambers. Columns, mean values; bar, SD. *p,0.01.
doi:10.1371/journal.pone.0024015.g002
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LoVo-LIPO recipients. However, the formation of lung metastases
in mice given LoVo-AKAP12 cells (6/10) was significantly lower
than the mice receiving either LoVo-CON (10/10) or LoVo-LIPO
(10/10) cells (Table 1). Additionally, lung tissue from mice injected
with LoVo-AKAP12 cells displayed significantly less human Alu
expression than LoVo-CON or LoVo-LIPO control group
(Fig. 3C). We also evaluated the expression of AKAP12 and
cleaved-caspase-3 level in the tumor tissues of LoVo-CON or
LoVo-AKAP12 group (Fig. 3D). The results indicate that Lovo-
AKAP12 group can significantly increase AKAP12 and cleaved-
caspase-3 level. These data indicated that ectopic expression of
AKAP12 in LoVo cells decreases their metastatic ability and
induced apoptosis in vivo.
Discussion
The biological role of AKAP12 in colorectal cancer progression
and metastasis is poorly understood. In the present study, we
examined this question through re-expression of AKAP12 in
AKAP12-null cancer cells to determine if this would influence
cancer cell growth and metastatic potential. AKAP12 inhibited cell
growth, migration, invasion, anchorage-independent growth and
induced apoptosis when transfected into LoVo cells. Furthermore,
injection of LoVo-AKAP12, LoVo-CON or LoVo-LIPO cells into
nude mice demonstrated that, in vivo, induced AKAP12 expression
in the colorectal cancer cells suppressed both tumor growth and
metastasis and induced apoptosis.
Cancer develops when the balance between cell proliferation and
cell death is disturbed, and aberrant cell proliferation leads to tumor
growth. In human gastriccancer cells, re-expression of AKAP12 lead
to reduced colony formation and apoptotic cell death[8]. To
examine whether modulation of AKAP12 expression influenced the
tumorigenic properties of the colorectal cancer cells, we tested in
vitro LoVo cell proliferation and apoptosis. As shown by both the
WST assay and FACS analysis, AKAP12 displays tumor-suppressive
activity in vitro. AKAP12-mediated suppression of tumor growth
may be achievedthrough director indirect interaction with multiple
apoptotic proteins and associated signaling pathways in cancer
cells[14]. These include several signaling molecules that participate
Figure 3. The effect of AKAP12 on the growth of human primary xenografts. (A) AKAP12 suppresses the growth of LoVo cells implanted in
BALB/c nude mice. Mice injected with LoVo-AKAP12 cells displayed significantly reduced tumor volume compared with the animals injected with
LoVo-CON or LoVo-LIPO cells four weeks after injection. (B) Tumor size was measured every week. Each point represents the mean volume 6 SD on
the X-axis. *p,0.01, LoVo-AKAP12 versus LoVo-CON versus LoVo-LIPO. p,0.01, LoVo-AKAP12 versus LoVo-CON. (C) Effect of AKAP12 expression on
the spontaneous metastasis of LoVo cells in nude mice. The quantitative real-time PCR amplification of the human Alu sequence and mouse GAPDH
was performed using DNA extracts from the lung. (D) Western blot analysis of AKAP12 and cleaved-caspase-3 level in Lovo-CON and Lovo-AKAP12
group. AKAP12 and cleaved-caspase-3 were found to increase in the Lovo-AKAP12 group.
doi:10.1371/journal.pone.0024015.g003
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kinase C (PKC), protein kinase A (PKA), cyclin D1 and
calmodulin[15–17]. In HT1080 cells, AKAP12 was found to
suppress tumor cell viability by inducing apoptosis via caspase-3
and was associated with a decreased expression of Bcl-2 and
increased expression of Bax[18]. Moreover, AKAP12 induced the
expression of Cip1/p21 and Kip1/p27 and decreased the
expression of cyclin D1[18]. SSeCKS, is the orthologue of human
AKAP12 gene, re-expression was reported to result in the
attenuation of critical Src-induced proliferative and pro-angiogenic
gene expression, including Afp and Cdc20a, and cell cycle
regulatory genes such as Ptpn11 and Gadd45a[19].
Cancer cells are capable of anchorage-independent growth and
are able to travel and settle in a new site in which the
microenvironment may be completely different[20,21], a process
crucial for oncogenesis and cancer metastasis. The re-expression of
AKAP12 in LoVo cells reduced colony formation and inhibited
anchorage-independent growth ability, which may explain the
contribution of AKAP12 to colorectal cancer progression. Howev-
er, in this study single clone data of a single cell line may be could
not describe the exact role of AKAP12 in the progression of
colorectal cancer and needs further exploration.
Distant metastases are the major cause of morbidity and
mortality in human colorectal cancer. AKAP12 may inhibit early
steps in metastatic colonization[22]. SSeCKS has been reported to
suppress lung metastasis of MatLyLu prostate cancer cells,
correlating with its suppression of VEGF–165 and -121
isoforms[23]. They also found that SSeCKS suppresses serum-
induced activation of the Raf/MEK/ERK pathway and down-
regulates matrix metalloproteinase (MMP)-2/9 expression and
secretion[24]. It also has been proposed that AKAP12/Gravin
functions as an essential scaffold for regulatory proteins that
suppress the migratory behavior of the mesoderm during
gastrulation in zebrafish embryos[25]. It has further been
suggested that this function explains how AKAP12 inhibits the
invasive behaviors of metastatic cells. In agreement with this
hypothesis, our results demonstrated that, in vitro, induced
expression of AKAP12 could reduce the invasion or migration
ability of oncogenic cells and significantly suppress the metastatic
potential of the colorectal cancer cells. AKAP12 also could inhibit
colorectal cancer tumorgenesis and metastasis in vivo and suggests
that AKAP12 may hold great promise for designing novel
therapeutic strategies against this solid cancer.
Our study indicates that AKAP12 is a suppressive factor in
colorectal cancer cells, inhibiting tumor cell growth and metastases
in vitro and in vivo. Collectively, these findings demonstrated that
AKAP12 may play an important role in the development of
malignancies. Therefore, AKAP12 could serve as an effective target
for the development of novel anti-cancer therapies and may be a
useful biomarker for human colorectal cancer.
Materials and Methods
Cell lines
The colorectal carcinoma cell line, LoVo, was obtained from
the American Type Culture Collection (ATCC, Manassas, VA,
USA). Cells were cultured in F12K media (GibcoBRL, Grand
Island, NY, USA) supplemented with 10% fetal bovine serum
(Sigma, St. Louis, MO, USA) and penicillin-streptomycin
(GibcoBRL). Cells were incubated in 5% CO2 at 37uC, and only
cells with a passage number of ,10 were used in the experiments.
Recombinant vectors and stable transfection
pCMV6-XL4-AKAP12 (Cat No. SC110078) was purchased
fromOrigene(Rockville,MD).Theplasmidswerepurified,digested
with NotI and subcloned into the pCMV6-Neo expression vector.
LoVo cells were transfected with the pCMV6-Neo-AKAP12
construct (LoVo-AKAP12), or the control empty vector (LoVo-
CON). For stable transfections, 10 mg of plasmid DNA was
resuspended in 500 ml of serum-free DMEM and mixed with
60 ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in
500 ml of serum-free DMEM. The mixture was incubated for
20 min at room temperature and added to a 70%-80% confluent
100-mm tissue culture dishes. After 2 h, the transfection medium
was changed to F12K medium containing 10% FBS. Transfection
efficiency was typically 60–80% as determined by GFP expression.
After 48 h, the transfection medium was changed to F12K medium
containing 10% FBS and antibiotic geneticin (G418) (400 mg/ml)
(Invitrogen Life Technologies, Inc., Carlsbad, CA). Clones were
screened by limited dilution cloning 4 days after selection. AKAP12
expression levels using Western blots, and one clone with vector
alone (LoVo-CON) and a clone overexpressing AKAP12 (LoVo-
AKAP12) were selected for further experiments.
Flow cytometry assay
Analysis of apoptosis was determined by flow cytometry. LoVo-
AKAP12 and LoVo-CON cells were seeded in six-well plates in
10% FBS/F12K and then incubated at 37uC. FACS analysis using
propidium iodide (PI) staining combined with Annexin V-FITC
(BD, Franklin Lakes, NJ, USA) was performed. First, 10
6 cells
were washed twice with cold PBS and resuspended in 16binding
buffer. Then, 10
5 cells were transferred to a 5 mL tube, 5 mLo f
Annexin V-FITC and PI were added and the cells were incubated
in the dark for 15 min at room temperature. Prior to FACS
analysis, 400 mLo f1 6 binding buffer were added. The
experiment was repeated three times.
Western blot analysis
Western blot analysis was performed as described previous-
ly[26]. Equala mounts of proteins from cells and tissues were
separated by SDS-PAGE gels and then transferred to PVDF
Table 1. Growth and metastatic ability of non-transfected and transfected LoVo cells in vivo.
Groups Tumor Lung metastases
Incidence
(growth/total) Final tumor size, cm
3±SD Metastasis formation (metastasis/total)
LoVo-AKAP12 10/10 0.04560.017*,** 6/10
LoVo-CON 10/10 0.25460.089 10/10
LoVo-LIPO 10/10 0.3460.102 10/10
*p,.01, LoVo-AKAP12 versus LoVo-CON and LoVo-LIPO.
**p,.01, LoVo-AKAP12 versus LoVo-CON.
doi:10.1371/journal.pone.0024015.t001
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the appropriate primary antibodies overnight (anti-cleaved-
caspase-3, 1:500, Cell Signaling; anti-b-actin, 1:500, Cell Signal-
ing; anti-human AKAP12, 1:500, Sigma). Following three washes
with TBST, the blots were incubated with the secondary
horseradish peroxidase-conjugated antibody (1:3000) at room
temperature for 1 h. Immunocomplexes were visualized by using
enhanced chemiluminescence (BioRad) following the manufactur-
er’s instructions. The bands were subsequently analyzed densito-
metrically with Quantity One Software (BioRad).
In vitro cell migration and invasion assay
Cell migration was evaluated using the QCM 24-Well
Colorimetric Cell Migration Assay Kit (Chemicon). In brief,
LoVo-AKAP12 and LoVo-CON cells were plated at a density of
16106 cells/mL on 8 mm inserts and cultured for 24 h. The non-
migrating cells were removed from the upper surface of the insert
with a cotton-tipped swab, and cells that have migrated are
incubated with stain solution. Transfer the stained insert to a clean
well containing 200 mL of Extraction Buffer for 15 minutes at
room temperature. Extract the stain from the underside by gently
tilting the insert back and forth several times during incubation.
Remove the insert from the well. Then the insert could be counted
manually through a microscope and five fields were evaluated for
migration. The experiment was repeated three times.
The invasive capability of the transfected cells was assessed
using Cell Invasion Assay Kit (Chemicon), a similar chemotaxis
chamber as above but with a few modifications. In brief, LoVo-
AKAP12 and LoVo-CON cells were plated at a density of
10
6 cells/mL on ECMatrix gel-coated polycarbonate membrane
inserts with an 8 mm pore size and cultured for 24 h. Invasive cells
migrate through the ECM layer and cling to the bottom of the
polycarbonate membrane. The non-invading cells and the
ECMatrix gel were removed from the upper surface of the insert
with a cotton-tipped swab. Add staining solution to the
unoccupied wells of the plate and stain invasive cells on lower
surface of the membrane by dipping inserts in the staining
solution. Dip inserts in a beaker of water several times to rinse.
Count cells by photographing the membrane through the
microscope and five fields were evaluated for invading cells. The
experiment was repeated three times.
Primary xenografts
To evaluate in vivo tumorigenesis, a colorectal cancer xenograft-
ingmousemodelwasused.FemaleBALB/cnudemiceoffourtosix
weeks old were prepared for tumor implantation. Mice were
allowed to acclimate for one week after arrival. All animals were
maintainedinasterileenvironmentona daily12-h light/darkcycle.
After resuspension in PBS, LoVo-AKAP12, LoVo-CON cells and
LoVo-LIPO (transfected with Lipofectmine only), 56106 cells/
mouse were injected subcutaneously into the flank of nude mice
(n=10/group). Tumor volume was calculated weekly for four
weeks according to the formula, TV (cm3) = length6width260.5.
The primary xenografts and lungs were harvested, weighed, and
snap-frozen[27]. All of the animal experiments were conducted in
strict accordancewiththe National Institute of Health Guide for the
Care and Use of Laboratory Animals.
Metastasis assay in vivo
The detection of the presence of human tumor cells in the lungs
of mice was achieved using the quantitative detection of human
Alu sequences present in total lung genomic DNA prepara-
tions[28]. Whole lungs were harvested and genomic DNA was
isolated using the DNeasy Tissue kit (Qiagen). Lung genomic
DNA was quantified in human tumor cells from the lungs using a
PCR-based detection of the human Alu sequences and, as a
control, GAPDH, and the following primers: Alu-F, 59-CACCTG-
TAATCCCAGCACTTT-39; Alu-R, 59-CCCAGGCTGGAGT-
GCAGT-39; GAPDH-F, 59- GCACAGTCAAGGCCGAGAAT-
39and GAPDH-R,59- GCCTTCTCCATGGTGGTGAA-39. PCR
was performed under the following conditions: 95uC for 2 min, 30
cyclesat95uCfor30 s,65uCfor20 s,and 72uCfor20 s.TheSYBR
Green PCR Master Mix (Qiagen) was used for the real-time PCR
amplification of the Alu sequences. A quantitative measure of
amplifiable mouse DNA was obtained through amplification of the
mouse GAPDH genomic DNA sequence. The fluoresence emitted
by the reporter dye was detected using the SYBR Green and the
thershold cycle (Ct) for each sample was recorded as a quantitative
measure of the amount of product in each sample. When indicated,
the Alu signal was normalized against the relative quantity of
GAPDH and expressed as DCt=(Ct
Alu–Ct
GAPDH). The changes in
Alu signal relative to the total amount of genomic DNA were
expressed as 2
22DCt, indicating the changes in the quantity of
human DNA in the mouse lung tissue. Data are shown as relative to
the expression of Alu and levels from the LoVo-LIPO group were
normalized to one. The specificity of human Alu PCR was verified
by the lack of amplification from 100% mouse DNA.
Statistical analysis
The Student’s t-test was used to compare the obtained values
with those from the corresponding control experiments and
p-values ,.05 was considered statistically significant.
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